摘要
目的探讨非小细胞肺癌患者血清人类表皮生长因子受体2（humanepidermalgrowthfactorreceptor2，HER2）和环氧化酶2（cycl00xygenase-2，COX2）水平相关性及与预后的关系。方法非小细胞肺癌患者221例（观察组）与肺部良性疾病患者41例（对照组），2组采用双抗体夹心ELISA法检测血清HER2和COX2水平，分析二者相关性及与生存时间的关系。结果观察组HER-2和COX-2水平明显高于对照组（P〈0．05）；观察组HER2阳性表达者中位生存时间（48．7周）较HER-2阴性表达者（62．3周）短；COX2阳性表达者中位生存时间（67．0周）较COX-2阴性表达者（83．1周）短（P〈0．05）；观察组HER2与CoX2水平呈正相关（r=0．717，P=0．007）；观察组HER-2和COX-2水平不是影响预后的独立危险因素，但二者联合检测可预测患者预后（OR=1．5，95％CI：1．08～2．09）。结论非小细胞肺癌与HER-2和COX2阳性表达明显相关，二者联合检测有助于非小细胞肺癌的预后评估。
Objective To explore the correlation between serum human epidermal growth factor receptor 2 （HER 2） and cyclooxygenase-2 （COX-2） as well as their relationship with the prognosis in patients with non small cell lung cancer （NSCLC）. Methods The levels of HER-2 and COX-2 were detected by using ELISA technique in 221 NSCLC patients （observation group） and 41 patients with benign lung disease （control group）, and were analyzed their correlation. The relationship of HER-Z and COX-2 with the suevival time was also analyzed. Results The levels of serum HER 2 and COX 2 were significantly higher in observation group than those in control group （P〈0.05）. The median survival time in the patients with positive HER-2 expression was 48.7 weeks, shorter than that in those with negative HER-2 expression （62.3 weeks）, and the median survival time in the patients with positive COX 2 expression was 67.0 weeks, shorter than that in those with negative COX 2 expression （83. 1 weeks） （P〈0.05）. HER-2 level was positively correlated with COX-2 level in observation group （r=0. 717, P =0. 007）, and both of them were not the independent risk factors for the prognosis. The combined detection could predict the prognosis （OR= 1. 5, 95;CI： 1. 08 to 2. 09）. Conclusion The positive expression of HER-2 is obviously correlated with the positive expression of COX-2 in NSCLC patients, and the combined detection of them may be of important value in the judgment of prognosis.
出处
《中华实用诊断与治疗杂志》
2013年第10期959-961,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
烟台市科技局基金项目(2009156-3)
